138 related articles for article (PubMed ID: 8580391)
1. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group.
Small GW; Hamilton SH; Bystritsky A; Meyers BS; Nemeroff CB
Int Psychogeriatr; 1995; 7 Suppl():41-53. PubMed ID: 8580391
[TBL] [Abstract][Full Text] [Related]
2. Predicting response to fluoxetine in geriatric patients with major depression.
Koran LM; Hamilton SH; Hertzman M; Meyers BS; Halaris AE; Tollefson GD; Downs JM; Folks DG; Jeste DV; Lazarus LW
J Clin Psychopharmacol; 1995 Dec; 15(6):421-7. PubMed ID: 8748431
[TBL] [Abstract][Full Text] [Related]
3. Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group.
Small GW; Birkett M; Meyers BS; Koran LM; Bystritsky A; Nemeroff CB
J Am Geriatr Soc; 1996 Oct; 44(10):1220-5. PubMed ID: 8856002
[TBL] [Abstract][Full Text] [Related]
4. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression.
Tollefson GD; Holman SL
Int Clin Psychopharmacol; 1993; 8(4):253-9. PubMed ID: 8277144
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients.
Sandor P; Baker B; Irvine J; Dorian P; McKessok D; Mendlowitz S
Depress Anxiety; 1998; 7(2):69-72. PubMed ID: 9614594
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
[TBL] [Abstract][Full Text] [Related]
8. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder.
Fava M; Alpert J; Nierenberg AA; Mischoulon D; Otto MW; Zajecka J; Murck H; Rosenbaum JF
J Clin Psychopharmacol; 2005 Oct; 25(5):441-7. PubMed ID: 16160619
[TBL] [Abstract][Full Text] [Related]
9. Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline.
Marchesi C; Ceccherininelli A; Rossi A; Maggini C
Pharmacopsychiatry; 1998 Nov; 31(6):216-21. PubMed ID: 9930635
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group.
Tollefson GD; Bosomworth JC; Heiligenstein JH; Potvin JH; Holman S
Int Psychogeriatr; 1995; 7(1):89-104. PubMed ID: 7579025
[TBL] [Abstract][Full Text] [Related]
11. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.
Gillin JC; Rapaport M; Erman MK; Winokur A; Albala BJ
J Clin Psychiatry; 1997 May; 58(5):185-92. PubMed ID: 9184611
[TBL] [Abstract][Full Text] [Related]
12. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression.
Heiligenstein JH; Ware JE; Beusterien KM; Roback PJ; Andrejasich C; Tollefson GD
Int Psychogeriatr; 1995; 7 Suppl():125-37. PubMed ID: 8580388
[TBL] [Abstract][Full Text] [Related]
13. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
[TBL] [Abstract][Full Text] [Related]
14. Moclobemide versus fluoxetine for double depression: a randomized double-blind study.
Duarte A; Mikkelsen H; Delini-Stula A
J Psychiatr Res; 1996; 30(6):453-8. PubMed ID: 9023788
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder.
Luo YL; Zhang MY; Wu WY; Li CB; Lu Z; Li QW
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1522-5. PubMed ID: 19733606
[TBL] [Abstract][Full Text] [Related]
16. Double-blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression.
Akhondzadeh S; Faraji H; Sadeghi M; Afkham K; Fakhrzadeh H; Kamalipour A
J Clin Pharm Ther; 2003 Oct; 28(5):379-84. PubMed ID: 14632962
[TBL] [Abstract][Full Text] [Related]
17. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Silverstone PH; Ravindran A
J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
[TBL] [Abstract][Full Text] [Related]
18. Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo.
Heiligenstein JH; Tollefson GD; Faries DE
J Affect Disord; 1994 Mar; 30(3):163-73. PubMed ID: 8006243
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.
Emslie GJ; Rush AJ; Weinberg WA; Kowatch RA; Hughes CW; Carmody T; Rintelmann J
Arch Gen Psychiatry; 1997 Nov; 54(11):1031-7. PubMed ID: 9366660
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine in the prevention of depressive recurrences: a double-blind study.
Gilaberte I; Montejo AL; de la Gandara J; Perez-Sola V; Bernardo M; Massana J; Martin-Santos R; Santiso A; Noguera R; Casais L; Perez-Camo V; Arias M; Judge R;
J Clin Psychopharmacol; 2001 Aug; 21(4):417-24. PubMed ID: 11476126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
